News & Updates

Show Multimedia Only

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

15 Aug 2025

At the recent COVID-CONNECT Masterclass, an expert-led session explored where COVID-19 stands among common viral infections today. In a non-promotional symposium supported by Pfizer, infectious disease specialist Dr Leong Hoe Nam, Mount Elizabeth Hospital Novena, Singapore, discussed strategies for managing viral infections and surge preparedness. Complementing this, Professor David Strain from the University of Exeter Medical School, UK highlighted the enduring burden of long COVID.

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

15 Aug 2025

Radiotherapy plus sacituzumab govitecan feasible in metastatic breast cancer

14 Aug 2025

Concurrent administration of sacituzumab govitecan and radiotherapy is well tolerated and does not lead to increased toxicity in patients with metastatic breast cancer, a study has shown.

Radiotherapy plus sacituzumab govitecan feasible in metastatic breast cancer

14 Aug 2025

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

14 Aug 2025 by

The E-STOP trial presented at ESHRE 2025 supports early antibiotic suspension in paediatric patients with cancer and febrile neutropenia (FN).

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

14 Aug 2025

Peg-filgrastim reduces neutropenia in children with solid tumours

13 Aug 2025

The incidence of febrile neutropenia (FN) is significantly lesser in children with solid tumours receiving pegylated filgrastim as primary prophylaxis following chemotherapy than in those assigned to filgrastim alone, reports a study. Moreover, no adverse events attributed to the study drug have been observed.

Peg-filgrastim reduces neutropenia in children with solid tumours

13 Aug 2025

Ultrashort inpatient TB prevention feasible in advanced HIV, cryptococcal meningitis patients

13 Aug 2025 by

The IMPROVE trial shows the feasibility and safety of 1-month isoniazid and rifapentine (1HP) in an inpatient setting as tuberculosis preventive therapy (TPT) in patients with advanced HIV disease (AHD) and cryptococcal meningitis (CM).

Ultrashort inpatient TB prevention feasible in advanced HIV, cryptococcal meningitis patients

13 Aug 2025

F/TAF plus cobicistat-boosted PIs maintained virologic suppression in children with HIV

13 Aug 2025 by

Treatment with emtricitabine/tenofovir alafenamide (F/TAF) and cobicistat-boosted atazanavir (ATV/c) or darunavir (DRV/c) maintained high rates of virologic suppression through 48 weeks in children living with HIV, based on two cohorts of the GS-US-216-0128 study presented at IAS 2025.

F/TAF plus cobicistat-boosted PIs maintained virologic suppression in children with HIV

13 Aug 2025

Vorasidenib prevents seizures in mIDH1/2 gliomas

12 Aug 2025 by

Patients with grade 2 isocitrate dehydrogenase 1 or 2 mutant (mIDH1/2) gliomas receiving vorasidenib experience fewer seizure activities than those on placebo, as shown by the results of the INDIGO study.

Vorasidenib prevents seizures in mIDH1/2 gliomas

12 Aug 2025

Eptinezumab eases migraine, medication-overuse headache

12 Aug 2025 by

Two separate randomized controlled trials (SUNRISE and RESOLUTION) have shown the superiority of eptinezumab over placebo in a predominantly Asian migraine population and in patients with chronic migraine (CM) and medication-overuse headache (MOH).

Eptinezumab eases migraine, medication-overuse headache

12 Aug 2025

Dual noninferior to triple ART in maintaining viral suppression among PLWH

12 Aug 2025 by

Switching to maintenance dual antiretroviral therapy (ART) with DTG+3TC* or ATV/r+3TC** was noninferior to continuing triple current ART with TDF+3TC+EFV*** or DTG+3TC+TDF⁺ in maintaining virologic suppression for up to 96 weeks among people living with HIV (PLWH), according to the MODERATO trial presented at IAS 2025.

Dual noninferior to triple ART in maintaining viral suppression among PLWH

12 Aug 2025

Periconceptional GLP-1RA exposure safety varies on indication for use

11 Aug 2025 by

Exposure to glucagon-like peptide 1 receptor agonists (GLP-1RAs) during pregnancy poses a modest increase in the risk of preterm birth in the context of diabetes treatment, but there is no evidence of increased obstetric complications when the drugs are exclusively used for weight management, according to new research.

Periconceptional GLP-1RA exposure safety varies on indication for use

11 Aug 2025

News & Updates

Filter by Specialty:

Specialty:

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

Radiotherapy plus sacituzumab govitecan feasible in metastatic breast cancer

Radiotherapy plus sacituzumab govitecan feasible in metastatic breast cancer

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

Peg-filgrastim reduces neutropenia in children with solid tumours

Peg-filgrastim reduces neutropenia in children with solid tumours

Ultrashort inpatient TB prevention feasible in advanced HIV, cryptococcal meningitis patients

Ultrashort inpatient TB prevention feasible in advanced HIV, cryptococcal meningitis patients

F/TAF plus cobicistat-boosted PIs maintained virologic suppression in children with HIV

F/TAF plus cobicistat-boosted PIs maintained virologic suppression in children with HIV

Vorasidenib prevents seizures in mIDH1/2 gliomas

Vorasidenib prevents seizures in mIDH1/2 gliomas

Eptinezumab eases migraine, medication-overuse headache

Eptinezumab eases migraine, medication-overuse headache

Dual noninferior to triple ART in maintaining viral suppression among PLWH

Dual noninferior to triple ART in maintaining viral suppression among PLWH

Periconceptional GLP-1RA exposure safety varies on indication for use

Periconceptional GLP-1RA exposure safety varies on indication for use